Nevro News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.08.24	Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray (RTTNews)
09.01.24	Nevro Expects Q4 Revenues To Grow 4%, To Lay Off 5% Of Workforce (RTTNews)
30.11.23	Nevro Announces Acquisition of Vyrsa™ Technologies (PR Newswire)
20.11.23	Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain (PR Newswire)
01.11.23	Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance (PR Newswire)
04.10.23	Nevro to Report Third Quarter 2023 Financial Results (PR Newswire)
18.09.23	New Data Show Health Economic Benefits Of Nevro's High-Frequency Spinal Cord Stimulation Therapy (RTTNews)
18.09.23	New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy (PR Newswire)
23.08.23	Nevro Announces Participation in Upcoming Investor Conferences (PR Newswire)
16.08.23	New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy (PR Newswire)
01.08.23	Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance (PR Newswire)
13.07.23	Nevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual Conference (PR Newswire)
12.07.23	Nevro to Present at the Canaccord Genuity 43rd Annual Growth Conference (PR Newswire)
27.06.23	Nevro to Report Second Quarter 2023 Financial Results (PR Newswire)
23.06.23	Nevro Announces Painful Diabetic Neuropathy Clinical Data Presentations at the American Diabetes Association 83rd Scientific Sessions (PR Newswire)
05.06.23	Nevro Names New Chief Commercial Officer (PR Newswire)
22.05.23	Nevro to Present at Jefferies Healthcare Conference (PR Newswire)
27.04.23	Nevro Corp. Announces New Employment Inducement Grant under Section 303A.08 of the NYSE Listed Company Manual (PR Newswire)
26.04.23	Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance (PR Newswire)
24.04.23	Nevro Announces Enrollment of First Patient in PDN Sensory Study (PR Newswire)
24.04.23	Nevro Announces Participation in Upcoming Investor Conferences (PR Newswire)
19.04.23	Nevro Names Kevin Thornal as New Chief Executive Officer and President (PR Newswire)
29.03.23	Nevro to Report First Quarter 2023 Financial Results (PR Newswire)
07.03.23	Nevro Announces U.S. Full Market Launch of Revolutionary HFX iQ™ Spinal Cord Stimulation System to Personalize Treatment of Chronic Pain (PR Newswire)
23.02.23	Nevro to Participate in Wells Fargo 2023 Medtech Innovation Spotlight Call Series (PR Newswire)
16.02.23	Nevro Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides First Quarter and Complete Full-Year 2023 Guidance (PR Newswire)
01.02.23	Nevro to Present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference (PR Newswire)
31.01.23	Nevro Named to 2023 Bloomberg Gender-Equality Index for Second Consecutive Year (PR Newswire)
19.01.23	Nevro to Report Fourth Quarter and Full-Year 2022 Financial Results (PR Newswire)
12.01.23	Nevro to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society (NANS) 26th Annual Meeting (PR Newswire)
09.01.23	Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue Guidance (PR Newswire)
19.12.22	Nevro to Present at 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
14.12.22	Nevro Announces Two Presentations from SENZA-PDN and SENZA-NSRBP Clinical Trials Have Been Accepted for Late-Breaking Abstract Sessions at NANS 2023 Annual Meeting (PR Newswire)
02.11.22	Nevro Reports Third Quarter 2022 Financial Results, Narrows Full-Year 2022 Guidance and Raises Revenue Contribution from Painful Diabetic Neuropathy (PR Newswire)
13.10.22	FDA Approves Nevro's HFX IQ Spinal Cord Stimulation System To Personalize Treatment Of Chronic Pain (RTTNews)
13.10.22	Nevro Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain (PR Newswire)
10.10.22	Nevro Comments on UnitedHealthcare Medical Coverage Policy Update (PR Newswire)
05.10.22	Nevro to Report Third Quarter 2022 Financial Results (PR Newswire)
05.10.22	Nevro :FDA Oks Manufacturing Operations In Costa Rica For Spinal Cord Stimulation Systems Production (RTTNews)
04.10.22	Nevro Announces FDA Approval of Costa Rica Manufacturing Operations (PR Newswire)
03.10.22	Nevro Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuro... (PR Newswire)
01.09.22	Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy (PR Newswire)
09.08.22	Nevro Announces Participation In Upcoming Investor Conferences (PR Newswire)
03.08.22	Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance (PR Newswire)
01.08.22	Nevro And Boston Scientific Reach $85 Mln Settlement Of Ongoing Intellectual Property Litigations (RTTNews)
01.08.22	Nevro and Boston Scientific Announce the Settlement of Their Ongoing Intellectual Property Litigations (PR Newswire)
21.07.22	Nevro to Present at the Canaccord Genuity 42nd Annual Growth Conference (PR Newswire)
06.07.22	Nevro to Report Second Quarter 2022 Financial Results (PR Newswire)
05.07.22	Newly Released Clinical Data Demonstrates Substantial Improvement in Overall Health-Related Quality of Life in Patients with Painful Diabetic Neuropathy Treated with Nevro HFX Spinal Cord Stimulat... (PR Newswire)
07.06.22	Clinical Data Presented at American Diabetes Association 82nd Scientific Sessions Reinforce Significant and Durable Benefits of Nevro's HFX 10 kHz Therapy (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Nevro Corp

Aktien Top/Flop

Meistgelesene Nachrichten